To see only press releases which have been disclosed pursuant to legislation or other regulations, please select “Regulatory releases” below.
Initiator Pharma A/S, a clinical-stage pharma company, announced today an update on its clinical programs IPED2015, IP2018 and IPTN2021 for erectile dysfunction and neuropathic pain. All programs are progressing according to plan, although full patient inclusion in the IP2018 Phase 2a trial is expected to occur in the first part of 2022.
Initiator Pharma A/S, a clinical-stage pharma company, announced today that a recent study published in the peer-reviewed scientific journal Nature shows the importance of dopaminergic neurons in the brain for sexual function (1). The findings support the mode of action used in Intiator Pharma’s IPED2015 and IP2018 clinical programs targeting erectile dysfunction of organic and psychogenic origin respectively.
Initiator Pharma receives CTA approval for IPTN2021 program Phase I study to assess pain reducing effects
Initiator Pharma A/S, a clinical-stage pharma company, announced today that it has received approval of a Clinical Trials Application for its planned Phase I study in the IPTN2021 program with the drug substance IP2015 in healthy subjects challenged with pain inducing ingredient (capsaicin).
Initiator Pharma A/S, a clinical-stage Life Sciences company, announced today, October 25, 2021, first trading day at Nasdaq First North Growth Market and new website.
The AGM held on May 28, 2021 approved a long-term incentive program (“LTI2021”) for key personnel and board members. Under this program the board is authorized to allow participants in the…
Initiator Pharma signs screening agreement with the US National Institute on Drug Abuse to evaluate anti-addictive properties of preclinical assets
September 17, 2021
Initiator Pharma A/S, a clinical-stage Life Science company, today announced that it has signed a screening agreeement with the National Institute on Drug Abuse (NIDA) in the USA in order to investigate the potential benefits of the company’s preclinical assets IPDP2015 and IPNP2015 for improved treatment of addiction.